NEW YORK, April 16, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation ("Celgene") (NASDAQ:CELG) between September 12, 2016 and February 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-d/celgene-corporation?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the trials for GED-0301 suffered from fatal design defects, such that GED-0301 had failed to demonstrate meaningful clinical efficacy; (3) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (4) the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
If you suffered a loss in Celgene you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Same sparkle, different story: how lab-grown diamonds are transforming the market
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Japan Earthquake Disrupts Auto and Chip Supply Chains
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Capital One Says AML Review Led to Closure of Trump Organization Accounts
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 



